Evofem Biosciences to Present at LD Micro Invitational XI on Tuesday, June 8, 2021

Evofem Biosciences, Inc. (NASDAQ: EVFM) announced that CEO Saundra Pelletier will present at the 2021 LD Micro Invitational XI on June 8, 2021, at 1:00 p.m. ET.

Rhea-AI Summary

Evofem Biosciences, Inc. (NASDAQ: EVFM) announced that CEO Saundra Pelletier will present at the 2021 LD Micro Invitational XI on June 8, 2021, at 1:00 p.m. ET. The presentation will focus on the commercialization of Evofem's hormone-free contraceptive Phexxi®, the Phase 3 clinical trial for EVO100 to prevent chlamydia and gonorrhea in women, and other initiatives. Interested participants can pre-register for the presentation at ldmicrojune2021.mysequire.com.

News Market Reaction – EVFM

-2.70%

-2.70% Session move

In the trading session that priced this news, EVFM declined 2.70%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 25, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that its CEO Saundra Pelletier will present at the 2021 LD Micro Invitational XI on Tuesday, June 8, 2021 at 1:00 p.m. ET (10:00 a.m. PT).

Pelletier will provide an update on the commercialization of Evofem's hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), the ongoing Phase 3 clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea in women, and other ongoing initiatives.

To pre-register for the presentation, please visit https://ldmicrojune2021.mysequire.com/.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). For more information, please visit evofem.com.

Phexxi^® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-ld-micro-invitational-xi-on-tuesday-june-8-2021-301298297.html

SOURCE Evofem Biosciences, Inc.

FAQ

When will Evofem Biosciences present at the LD Micro Invitational XI?

Evofem Biosciences will present at the LD Micro Invitational XI on June 8, 2021, at 1:00 p.m. ET.

What will be discussed in the Evofem presentation?

The presentation will discuss the commercialization of Phexxi®, the ongoing Phase 3 clinical trial for EVO100, and other initiatives.

How can I pre-register for the Evofem presentation?

You can pre-register for the presentation at ldmicrojune2021.mysequire.com.

What is Phexxi® by Evofem Biosciences?

Phexxi® is a hormone-free contraceptive developed by Evofem Biosciences, designed for women's sexual and reproductive health.

What is the stock symbol for Evofem Biosciences?

The stock symbol for Evofem Biosciences is EVFM.